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SUMMARY
OBJECTIVE—To evaluate the association between oral candidiasis and tuberculosis (TB) in
human immunodeficiency virus (HIV) infected individuals in sub-Saharan Africa, and to
investigate oral candidiasis as a potential tool for TB case finding.
METHODS—Protocol A5253 was a cross-sectional study designed to improve the diagnosis of
pulmonary TB in HIV-infected adults in high TB prevalence countries. Participants received an
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oral examination to detect oral candidiasis. We estimated the association between TB disease and
oral candidiasis using logistic regression, and sensitivity, specificity and predictive values.
RESULTS—Of 454 participants with TB culture results enrolled in African sites, the median age
was 33 years, 71% were female and the median CD4 count was 257 cells/mm3. Fifty-four (12%)
had TB disease; the prevalence of oral candidiasis was significantly higher among TB cases (35%)
than among non-TB cases (16%, P < 0.001). The odds of having TB was 2.4 times higher among
those with oral candidiasis when controlling for CD4 count and antifungals (95%CI 1.2–4.7, P =
0.01). The sensitivity of oral candidiasis as a predictor of TB was 35% (95%CI 22–48) and the
specificity 85% (95%CI 81–88).
CONCLUSION—We found a strong association between oral candidiasis and TB disease,
independent of CD4 count, suggesting that in resource-limited settings, oral candidiasis may
provide clinical evidence for increased risk of TB and contribute to TB case finding.
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THE IDENTIFICATION of human immunodeficiency virus (HIV) infected persons with
low CD4+cell count is important in areas of high tuberculosis (TB) prevalence, as this group
is at highest risk of having TB disease concomitantly with HIV infection. Several studies
have shown that oral candidiasis and TB disease were the most common comorbidities
among populations with advanced HIV disease: one study among 356 hospitalized
Cambodian patients with the acquired immunedeficiency syndrome (AIDS) revealed that
oral candidiasis (51%) and pulmonary and extra-pulmonary TB (44%) were the most
frequent opportunistic infections.1 Another study among 205 HIV-infected adults in
Malaysia showed that oral candidiasis was the most common mucocutaneous disease, and
significant co-existence was found with the major opportunistic systemic diseases such as
TB.2
Early in the HIV epidemic, oral candidiasis was found to be among the strongest clinical
predictors of progression to AIDS in various HIV-infected populations.3,4 Oral candidiasis
has also been shown to be the most common oral manifestation of HIV infection in different
parts of the world,5–14 and to be closely associated with low CD4+ cell count.5,7,8,15–20 A
diagnosis of oral candidiasis is usually made by visual examination of the mouth, and non-
dental health care providers can be readily trained to perform such an examination.19 The
strong positive association between oral candidiasis and a low CD4+cell count is thus a
useful finding with respect to the need for inexpensive surrogate markers of HIV disease
progression and related comorbidities in resource-limited countries where measurement of
CD4+cell counts is not widely available.
A visual inspection of the soft tissues of the mouth is quick (<5 min), non-invasive, and
inexpensive. It could be used as initial screening to identify patients with oral candidiasis
who are most likely to have CD4+cell count <200 cells/mm3, and thus at higher risk for TB
disease that may or may not yet be symptomatic.
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The objective of the present study was to evaluate the value of oral candidiasis as a predictor
of TB disease among HIV-infected men and women in resource-limited settings with high
TB prevalence.
METHODS
Study design and population
This study was conducted as part of the AIDS Clinical Trial Group (ACTG) Protocol A5253
in collaboration with the Oral HIV/AIDS Research Alliance (OHARA).21 Protocol A5253
was a cross-sectional study designed to construct a standardized diagnostic evaluation (SDE)
that improves diagnosis of pulmonary TB as compared to standard-of-care (SOC) TB
screening in HIV-infected participants not currently receiving antiretroviral therapy
(ART).22
The target population for Protocol A5253 was HIV-infected males and females aged ≥13
years living in high TB prevalence regions in sub-Saharan Africa, India and South America.
In addition to being HIV-infected, eligibility criteria included not having received ART, or a
diagnosis of pulmonary TB, or medications to treat TB within 90 days before study entry.
Participants were recruited between 5 February and 30 November 2010 from 11 clinical
trials units of the ACTG by clinical site investigators using a convenience sampling strategy.
Sites were required to be in a country with a TB incidence of >60 per 100 000 population
per year according to the World Health Organization (WHO) Global Health Atlas country
profiles.23 The institutional review boards or ethics committees of the participating
institutions approved the study, and each participant gave written informed consent. The
present report focuses on the African sites only, as 96% of the TB cases were observed in
these sites.
Clinical data collection
All participants in Protocol A5253 were screened according to SOC and candidate SDE
elements.22 Sputum culture in either solid or liquid culture was used as the gold standard to
define a participant as TB-positive. SOC screening algorithm components were cough,
fever, weight loss and/or night sweats occurring within the previous 30 days, Ziehl-Neelsen
sputum smear and chest radiography (CXR) for non-pregnant participants. SDE screening
included additional symptoms and clinical signs, and sputum smear using fluorescence
microscopy. All participants underwent all evaluations. A detailed description of these
methods has been published elsewhere.22
All participants also underwent a standardized oral soft tissue examination performed by a
nurse or a physician who had been trained and calibrated in the diagnosis of common HIV-
related oral mucosal diseases using a protocol developed by the Clinical Science Unit of
OHARA. Examiners were trained by watching a 1-h presentation that described how to
perform an oral soft tissue examination, and how to diagnose pseudomembranous
candidiasis, erythematous candidiasis and angular cheilitis, which are all part of the
spectrum of oral candidiasis, as well as other common oral lesions. We used published case
definitions of these oral endpoints.24 Examiners were considered calibrated if they obtained
Shiboski et al. Page 3






















80% correct answers to a post-test of clinical slides administered after the training.
Participants found to have clinical signs of oral candidiasis had a swab (BBL™ Culture-
Swab™ kit, BD, Sparks, MD, USA) collected from a well-defined area for culture
confirmation of the clinical diagnosis. If a participant had more than one form of oral
candidiasis, the examiner was instructed to preferentially collect a swab from a
pseudomembranous candidiasis lesion if present. If pseudomembranous candidiasis was not
present, but angular cheilitis was observed together with erythematous candidiasis, then the
examiner was instructed to collect the swab from the angular cheilitis.
Oral swab specimen processing
Collection supplies were distributed to clinical trial sites from the OHARA/ACTG Candida
repository at the Center for Medical Mycology, Case Western Reserve University,
Cleveland, OH, USA. These consisted of culturette swabs containing Amies Transport
Media (Becton Dickinson, Franklin Lakes, NJ, USA), dehydrated potato dextrose agar
(PDA) (BD) and 4 ml Wheaton vials for preparing agar slants (Wheaton Industries,
Millville, NJ, USA). After collection, oral swabs were forwarded to a local laboratory for
processing onto PDA (potato dextrose agar) plates for Candida colony count, which were
recorded. A subculture of each distinct colony type suspected of being a Candida isolate was
then prepared on an agar slant and forwarded to the Case repository for speciation.
Statistical analyses
Summary statistics were used to describe participant characteristics (sex, age, region of
residence and CD4 cell count) by TB disease status. We computed the prevalence of the
three types of oral candidiasis and of other oral mucosal lesions, and used the χ2 test (or
Fisher’s exact test for smaller cell sizes) to explore whether an association existed between
these oral outcomes and TB. We fit a stepwise logistic regression model to investigate the
association between oral candidiasis and TB disease while controlling for potential
confounders. We started by fitting a model in which we included all variables that were
suspected confounders of the association between oral candidiasis and TB: CD4 cell count,
sex, age and receipt of antifungal medication at the time of study examination. We then
performed backward elimination analysis to remove variables that were not associated with
TB at a significance level of 0.2. The model yielded adjusted odds ratios (aORs) with 95%
confidence intervals (CIs). We initially also included an interaction term in the logistic
regression model to detect whether a possible effect modification existed between CD4 cell
count and oral candidiasis, but found no significant interaction effect (P = 0.33). To
investigate the role of oral candidiasis as a predictor of TB, we estimated the sensitivity,
specificity, and positive (PPV) and negative predictive values (NPV) in relation to TB.
RESULTS
Among 521 participants enrolled in Protocol A5253 in African sites, 455 had an
interpretable TB sputum culture result, and 454 underwent an oral examination (and are
included in the present report). The majority were Black non-Hispanic (99%) and female
(71%); 54 had culture-confirmed TB disease (12%; Table 1); 18% had a clinical diagnosis
of oral candidiasis. The median age was 33 years, and the median CD4+ cell count was 257
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cells/mm3. As previously reported, participants with and those without TB were similar with
regard to age and sex; however, the median CD4 cell count was significantly lower among
TB cases (202 cells/mm3, range 2–699) than in non-cases (270 cells/mm3, range 1–1796, P
= 0.003).22 Among participants with TB, 2% were using an antifungal medication at the
time of study entry compared to 9% among those without TB (P = 0.10).
The prevalence of oral candidiasis was significantly higher among TB cases (35%) than
among non-cases (16%; P < 0.001), predominantly pseudomembranous candidiasis (Table
2). Among 77 cases with a clinical diagnosis of oral candidiasis who had a swab collected
for culture (4 cases did not have a confirmatory swab), 62 (81%) were culture-confirmed.
The proportion of confirmation using culture differed by type of candidiasis, with angular
cheilitis and pseudomembranous candidiasis having the highest level of culture confirmation
(100% and 85%, respectively), and erythematous candidiasis the lowest (72%).
Other types of oral lesions had low prevalence (≤4% for each type of condition), and
included hairy leukoplakia (n = 7), recurrent herpes simplex infection (n = 6), necrotizing
ulcerative gingivitis/periodontitis (n = 6), oral Kaposi‘s sarcoma (n = 3), oral warts (n = 2)
and recurrent aphthous ulcers (n = 1).
Among those with oral candidiasis, 68% had a CD4 cell count <200 cells/mm3, while
among those without oral candidiasis 74% had a CD4 cell count >200 cells/mm3 (Table 3).
We found a strong positive association between low CD4 cell count and the presence of oral
candidiasis, using a contingency table approach or a non-parametric analysis.
A multivariate logistic regression model exploring the association between TB (outcome)
and oral candidiasis revealed that the odds of having TB was 2.4 times higher among those
with oral candidiasis when controlling for CD4 count and antifungal medication (95%CI
1.2–4.7, P = 0.01; Table 4).
The proportion of participants with TB who also had oral candidiasis (sensitivity) was 35%
(95%CI 22–48). The specificity was 85% (95%CI 81–88). Both PPV and NPV of oral
candidiasis in relation to TB are presented as functions of TB prevalence in the Figure. For
example, for a TB prevalence ranging from 10% to 15%, the PPV would range from 20% to
29%, and if TB prevalence was as high at 20%, the PPV of oral candidiasis would be 37%.
DISCUSSION
This analysis among HIV-infected participants in ACTG Protocol A5253 revealed that oral
candidiasis was the most common type of oral mucosal disease. Furthermore, as reported in
other studies in sub-Saharan Africa, there was a strong positive association between the
presence of oral candidiasis and low CD4 cell count.19 Clinical diagnoses of oral candidiasis
made by nurses and physicians at various ACTG sites, which were confirmed by a positive
culture in more than 80% of the cases, were strongly associated with TB even after adjusting
for CD4 count. The sensitivity was only 35%, while the specificity was 85%. The sensitivity
of oral candidiasis was somewhat similar to that of other clinical symptoms described in the
primary A5253 paper, such as fever, night sweats and fatigue, which were 43%, 48% and
50%, respectively.22 The specificity for these symptoms was lower than that of oral
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candidiasis: 71%, 61% and 60%, respectively. Furthermore, while a history of cough in the
last 30 days had the highest sensitivity of all clinical symptoms (82%), specificity was low
(39%). In the A5253 primary paper, performance characteristics were assessed for multiple
combinations of clinical symptoms, CD4 cell count, CXR and/or lymphadenopathy. None of
these combinations improved upon the predictive values of symptoms of cough, fever, night
sweats and fatigue, which are used in TB case finding. The present analysis reveals that due
to its strong association with TB disease and high specificity, and despite its modest
sensitivity, oral candidiasis should also prompt further evaluation for TB disease among
HIV-infected adults.
The strength of the present study is that it specifically explored the association between oral
candidiasis and TB by including a systematic oral examination among all participants,
regardless of oral symptoms. Furthermore, the clinical diagnosis of oral candidiasis was
confirmed by an oral swab culture, and revealed a high proportion of correct clinical
diagnoses. Oral examinations were performed by nurses/physicians who had received the
same standardized training on the diagnosis of the various forms of oral candidiasis.24 The
standardized oral examination training module has been evaluated within ACTG clinical
research sites (CRS) as part of a recent study to assess the accuracy of oral diagnoses made
by CRS examiners (non-dental health care professionals). Among 328 HIV-infected
participants, the sensitivity and specificity for the diagnosis of oral candidiasis by trained
CRS examiners as compared to Oral Medicine specialists as reference standard was 90%
and 92%, respectively, with 153 cases of oral candidiasis diagnosed in this cross-sectional
study (unpublished data). The limitations of our study include a potential lack of power, as
there were only 54 cases of TB. Use of sputum culture as reference standard excluded cases
of extra-pulmonary disease. The proportion of participants currently taking an antifungal
medication (8%) may have slightly diluted the magnitude of the association, although there
was no evidence of preferential bias as these participants were evenly distributed by TB
status.
The WHO, the Joint United Nations Programme on HIV/AIDS and the Stop TB Partnership
have set a target of halving TB mortality rates among HIV-positive people by 2015
compared to 2004.25 WHO recommendations on the interventions needed to prevent,
diagnose and treat TB in people living with HIV have been available since 2004.26 The plan
recommends that all people living with HIV should be regularly screened for TB using a
clinical symptom-based algorithm consisting of current cough, fever, weight loss or night
sweats at the time of initial presentation for HIV care and at every visit to a health care
facility or contact with a health care worker afterwards. Oral candidiasis is strongly
associated with TB disease, and can be assessed by a quick visual examination of the mouth.
Like other clinical symptoms, it therefore represents a useful clinical marker to identify a
high-risk population who must be screened for TB disease. While many studies have
reported on the strong association between oral candidiasis and low CD4 cell count, the
present study is among the first to detect a strong association between oral candidiasis and
TB disease after controlling for CD4 cell count. It is consistent with findings from a study of
2086 adults with HIV disease in South Africa that revealed that TB and oral candidiasis
were the only opportunistic infections to commonly occur among those with CD4 cell
counts ≥200 cells/mm3.27 Among those with CD4 cell count between 201 and 350
Shiboski et al. Page 6






















cells/mm3, the incidence rate of TB and oral candidiasis was 5.7 (95%CI 3.7–7.8) and 15.2
(95%CI 11.6–18.8) per 100 person-years, respectively, while all other opportunistic
infections had an incidence rate of <2.5.
Based on the modest sensitivity and PPV reported by our study, oral candidiasis cannot be
used as a diagnostic test for TB disease. However, the strong association found between the
presence of oral candidiasis and TB disease independently of CD4 cell count, and the high
specificity of oral candidiasis in relation to TB, suggest that it could be used to identify those
who should be screened for TB disease, for example with culture and/or nucleic acid
amplification tests. Consideration may also be given to use of the urine lipoarabinomannan
assay, which has high sensitivity among patients with advanced immunodeficiency.28 In
resource-limited countries, it is useful to have a clinical tool that may help identify those at
highest risk for TB, and we recommend that TB screening be performed on all HIV-infected
patients with a diagnosis of oral candidiasis.
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PPVs and NPVs of clinical diagnosis of oral candidiasis in predicting TB in the Africa sites
participating in Protocol A5253. PPV = positive predictive value; OC = oral candidiasis; TB
= tuberculosis; NPV = negative predictive value; CI = confidence interval.
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Table 1





  Black Non-Hispanic 451 (99)
  Hispanic (any race) 2 (<1)
  Asian/Pacific Islander 1 (<1)
 Sex
  Female 321 (71)
  Male 133 (29)
 Sputum culture-positive for tuberculosis 54 (12)
 Oral candidiasis
  Clinical diagnosis 81 (18)
  Culture-confirmed diagnosis† 62 (14)
 Currently on antifungal medication 36 (8)
Continuous variables, median (range)
 Age 33 (18–65)
 CD4 cell count 257 (1–1796)
*
Among 455 participants with interpretable sputum culture in Africa sites in Protocol A5253, 454 underwent an oral examination.
†
n = 77 underwent an oral swab culture to confirm the clinical diagnosis of oral candidiasis.
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Table 2
Prevalence of oral candidiasis and other oral mucosal lesions by TB status (as determined using sputum
culture) among 454 participants in Protocol A5253
Oral lesion (clinical diagnosis)
TB-positive (n = 54)
n (%)
TB-negative (n = 400)
n (%) P value
Candidiasis
 Any oral candidiasis 19 (35) 62 (16) <0.001*
 Pseudomembranous candidiasis 18 (33) 48 (12) <0.001*
 Erythematous candidiasis 2 (4) 16 (4) 1.00†
 Angular cheilitis 0 (0) 5 (1) 1.00†
Other oral mucosal lesions
 Hairy leukoplakia 1 (2) 6 (2) 0.59†
 Necrotizing ulcerative gingivitis/periodontitis 2 (4) 4 (1) 0.15†
 Recurrent oral/labial herpes simplex infection 2 (4) 4 (1) 0.15†
 Kaposi’s sarcoma 0 (0) 3 (<1) 1.00†
 Oral warts 0 (0) 2 (<1) 1.00†
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Table 3
Baseline characteristics by diagnosis of oral candidiasis among 454 participants with an interpretable sputum
culture in Protocol A5253 (sub-Saharan Africa sites)*
Characteristic
Oral candidiasis (n = 81)
n (%)
No oral candidiasis (n = 373)
n (%) P value†
Categorical variables
 Race/ethnicity
  Black non-Hispanic 81 (100) 370 (99) 1.000
  Hispanic (any race) 0 (0) 2 (1)
  Asian/Pacific Islander 0 (0) 1 (<1)
 Sex
  Female 53 (65) 268 (72) 0.250
  Male 28 (35) 105 (28)
 CD4 cell count, cells/mm3
  <200 55 (68) 96 (26) <0.001
  200–500 22 (27) 202 (54)
  >500 4 (5) 75 (20)
 Currently on antifungal medication 8 (10) 28 (8) 0.496
Continuous variables, median (Q1, Q3)‡
 Age 35 (29, 40) 32 (28, 39) 0.108
 CD4 cell count 151 (46, 228) 287 (190, 463) <0.001
*
Among 455 participants with interpretable sputum culture result in African sites in Protocol A5253, 454 underwent an oral examination.
†
Fisher’s exact test for race and CD4 cell count; χ2 test for sex.
‡
P values using Wilcoxon’s rank-sum test.
Q = quartile.
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Table 4
Multivariate model exploring the association between tuberculosis (outcome) and oral candidiasis controlling
for CD4 cell count, and antifungal medication among 454 Protocol A5253 participants recruited from African
sites
Independent variables aOR (95%CI) P value
Clinical diagnosis of oral candidiasis (vs. no oral candidiasis) 2.38 (1.22–4.66) 0.01
CD4 cell count, cells/mm3 (per 50 unit increase) 0.92 (0.84–0.99) 0.04
Antifungal medication (yes vs. no) 0.16 (0.02–1.19) 0.07
aOR = adjusted odds ratio; CI = confidence interval.
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